GGrantIndex
← Leaderboards

Michael R McNeil

Colorado State University-Fort Collins

Google Scholar ↗PubMed ↗ORCID ↗
$4,500,958
Attributed
$4,500,958
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.7M · FY2005–09
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$9,042,165 · 10

By mechanism

P01$5,938,980 · 3
R01$2,543,315 · 1
R21$366,250 · 2
R03$193,620 · 4

Top collaborators

No co-investigators on record.

Most similar at Colorado State University-Fort Collins

Same institution · by research overlap

Others in their field

Top investigators on “Mycobacterium Tuberculosis”

Research focus

Mycobacterium TuberculosisEnzyme InhibitorsCell WallAntitubercular AgentsCarbohydrate BiosynthesisTuberculosisArabinoseX Ray CrystallographyMicroorganism MetabolismBacterial GeneticsDrug Discovery /IsolationCombinatorial ChemistryTransferaseLaboratory MouseEnzyme ActivityDrug Design /Synthesis /ProductionEnzymesPharmaceutical PreparationsProtein PurificationMicroorganism Disease ChemotherapyInhibitor/AntagonistMicroorganism GrowthBioterrorism /Chemical WarfareEnzyme Inhibitor Drugs

Grant awards (29)

HTS assay and configuration for inhibitors of the UDP-Mur formation pathway$147,000
R21 · FY2009 · NS · contact PI
Multi-Drug Resistant Tuberculosis Drugs: Targeting Cell Wall Synthetic Enzymes$906,176
P01 · FY2008 · AI · contact PI
Developing Tuberculosis (TB) Cell Wall Enzyme Drug Targets$254,982
P01 · FY2008 · AI · contact PI
Glucosamine-1-phosphate and serine acetylases: HTS assays and configurations$36,750
R21 · FY2008 · NS · contact PI
Multi-Drug Resistant Tuberculosis Drugs: Targeting Cell Wall Synthetic Enzymes$877,762
P01 · FY2007 · AI · contact PI
Developing Tuberculosis (TB) Cell Wall Enzyme Drug Targets$246,985
P01 · FY2007 · AI · contact PI
HTS Screen of TB RmlC & RmlD dTDP-Rhamnose Formation Enzymes$25,000
R03 · FY2007 · DA · contact PI
MDR-TB Drugs: Targeting Cell Wall Synthetic Enzymes$879,709
P01 · FY2006 · AI · contact PI
Cell Wall Biogenesis-Target for new Anti-TB drugs$393,224
R01 · FY2006 · AI · contact PI
Developing TB Cell Wall Enzyme Drug Targets$253,491
P01 · FY2006 · AI · contact PI
Glucosamine-1-phosphate and serine acetylases: HTS assays and configurations$182,500
R21 · FY2006 · NS · contact PI
MDR-TB Drugs: Targeting Cell Wall Synthetic Enzymes$876,763
P01 · FY2005 · AI
Cell Wall Biogenesis-Target for new Anti-TB drugs$391,446
R01 · FY2005 · AI
Developing TB Cell Wall Enzyme Drug Targets$246,703
P01 · FY2005 · AI
D-arabinose synthesis in TB using Azorhizobium as a tool$33,040
R03 · FY2005 · TW
MDR-TB Drugs: Targeting Cell Wall Synthetic Enzymes$1,000,797
P01 · FY2004 · AI
Cell Wall Biogenesis-Target for new Anti-TB drugs$383,928
R01 · FY2004 · AI
Developing TB Cell Wall Enzyme Drug Targets$281,604
P01 · FY2004 · AI
D-arabinose synthesis in TB using Azorhizobium as a tool$33,040
R03 · FY2004 · TW
Cell Wall Biogenesis-Target for new Anti-TB drugs$372,915
R01 · FY2003 · AI
D-arabinose synthesis in TB using Azorhizobium as a tool$39,540
R03 · FY2003 · TW
Cell Wall Biogenesis-Target for new Anti-TB drugs$373,474
R01 · FY2002 · AI
TB DRUGS VIA INHIBITORS OF CELL WALL SYNTHETIC ENZYMES$0
P01 · FY2002 · AI
CELL WALL BIOGENESIS--TARGET FOR NEW ANTITB DRUGS$318,807
R01 · FY2001 · AI
TB DRUGS VIA INHIBITORS OF CELL WALL SYNTHETIC ENZYMES$0
P01 · FY2001 · AI
CELL WALL BIOGENESIS--TARGET FOR NEW ANTITB DRUGS$309,521
R01 · FY2000 · AI
TB DRUGS VIA INHIBITORS OF CELL WALL SYNTHETIC ENZYMES$114,008
P01 · FY2000 · AI
X RAY STRUCTURE OF UDP GALACTOPYRANOSE MUTASE$31,500
R03 · FY2000 · TW
SYNTHESIS OF MYCOBACTERIAL ARABINOFURANOSYL METABOLITES$31,500
R03 · FY2000 · TW